FATE (STOCKS)
Fate Therapeutics, Inc.
$1.421800
+0.181800 (+14.66%)
Prev close: $1.240000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Bahram Valamehr
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $152.31M
- Employees
- 181
- P/E (TTM)
- -1.14
- P/B (TTM)
- 0.69
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
6
Buy
7
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.27 | $-0.28 | +0.0051 | +1.85% |
|
Sep 2025 (Q3)
|
$-0.27 | $-0.30 | +0.0269 | +9.06% |
|
Jun 2025 (Q2)
|
$-0.29 | $-0.35 | +0.0593 | +16.98% |
|
Mar 2025 (Q1)
|
$-0.32 | $-0.39 | +0.0707 | +18.10% |
Financial Statements
| Revenues | $6.65M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $154.35M |
| Operating Expenses | $154.35M |
| Research and Development | $107.83M |
| Other Operating Expenses | $46.52M |
| Operating Income/Loss | -$147.70M |
| Income/Loss From Continuing Operations After Tax | -$136.32M |
| Income/Loss From Continuing Operations Before Tax | $6.65M |
| Income Tax Expense/Benefit | $2.00K |
| Net Income/Loss | -$136.32M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$136.32M |
| Net Income/Loss Available To Common Stockholders, Basic | -$136.32M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.15 |
| Diluted Earnings Per Share | -$1.15 |
| Basic Average Shares | 118,789,974 |
| Diluted Average Shares | 118,789,974 |
| Assets | $318.94M |
| Current Assets | $208.70M |
| Noncurrent Assets | $110.23M |
| Fixed Assets | $56.93M |
| Other Non-current Assets | $53.31M |
| Liabilities | $111.75M |
| Current Liabilities | $36.07M |
| Accounts Payable | $2.66M |
| Other Current Liabilities | $33.42M |
| Noncurrent Liabilities | $75.68M |
| Equity | $207.18M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $207.18M |
| Liabilities And Equity | $318.94M |
| Net Cash Flow From Operating Activities | -$106.08M |
| Net Cash Flow From Operating Activities, Continuing | -$106.08M |
| Net Cash Flow From Investing Activities | $111.17M |
| Net Cash Flow From Investing Activities, Continuing | $111.17M |
| Net Cash Flow From Financing Activities | $5.49M |
| Net Cash Flow From Financing Activities, Continuing | $5.49M |
| Net Cash Flow | $10.57M |
| Net Cash Flow, Continuing | $10.57M |
| Comprehensive Income/Loss | -$136.47M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$136.47M |
| Other Comprehensive Income/Loss | -$152.00K |